TransMedics, Inc. Appointed Jeffrey E. Young as Chief Financial Officer
ANDOVER, Mass., Nov. 8, 2013 /PRNewswire/ — TransMedics, Inc., an emerging medical technology company dedicated to extending the life-saving benefits of organ transplantation to patients suffering from end-stage organ failure, announced today that Jeffrey E. Young was appointed to the position of Chief Financial Officer and Treasurer, effective August 2013. Mr. Young, is responsible for the Company’s finance, accounting, and treasury functions and reports directly to Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics, Inc.
“We are excited to have Jeff on our team. Jeff’s experience as a senior leader within commercial companies is a good asset as TransMedics continues to expand its global commercial operations and drive shareholder value,” said Hassanein.
During his career, Mr. Young has held a variety of senior executive roles in the life sciences industry. From 2008 to 2013, Mr. Young served in a number of senior executive roles at Lantheus Medical Imaging, including Chief Financial Officer from 2012 to 2013. Lantheus Medical Imaging develops, manufactures and distributes diagnostic imaging agents worldwide. Prior to his time with Lantheus, Mr. Young spent three years at Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases, where he was Chief Accounting Officer. Prior to 2005, he served in a number of roles at PerkinElmer, Inc. Mr. Young’s prior positions included roles within the Capital Markets Group and Transaction Services Group of PricewaterhouseCoopers from 1996 to 2002. Mr. Young holds a Bachelor of Science in Business Administration degree from Georgetown University in Washington D.C.
“This is a great time to be joining TransMedics as the company builds on the momentum of the global thoracic pivotal trials to hopefully gain U.S. FDA clearance for our thoracic technology platform and expand into the abdominal organs,” said Mr. Young. “I look forward to working closely with Waleed and the entire TransMedics team to further accelerate our commercial growth strategy.”
About TransMedics, Inc.
TransMedics is a privately held medical technology company dedicated to extending the life-saving benefits of organ transplantation to patients suffering from end-stage organ failure. Headquartered in Andover, Massachusetts, the company was founded in 1998 to address the unmet need for better organ transplant technologies. The Organ Care System(TM) (OCS(TM)) is designed to help increase the number of organs utilized for transplantation, improve the health of organs being transplanted, improving outcomes and reducing recovery time, and lessen reliance on ongoing medical therapies. The system has CE Marking in Europe and is in routine commercial use for both the OCS Heart and OCS Lung systems. Pivotal IDE clinical trials are being concluded and marketing applications are being prepared for the FDA applications in the United States. For more information, please visit www.TransMedics.com.
SOURCE TransMedics, Inc.